Pancytopenia, a complication of Gleevec in treatment of accelerated and chronic phase CML.

被引：0
|
作者：
Zalzaleh, G [1 ]
Jajeh, A [1 ]
机构：
[1] Cook Cty Hosp, Chicago, IL 60612 USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4962
引用
收藏
页码：310B / 310B
页数：1
相关论文
共 50 条
  • [1] The impact of clonal evolution on response to imatinib mesylate (Gleevec) in accelerated phase CML.
    O'Dwyer, ME
    Mauro, MJ
    Kurilik, G
    Balleisen, S
    Capdeville, R
    Druker, BJ
    BLOOD, 2001, 98 (11) : 139A - 139A
  • [2] Preliminary evaluation of the combination of imatinib mesylate (Gleevec) in combination with low dose interferon-alpha for the treatment of chronic phase CML.
    O'Dwyer, ME
    Mauro, MJ
    Kuyl, JM
    Paquette, R
    Sawyers, CL
    Druker, BJ
    BLOOD, 2001, 98 (11) : 846A - 846A
  • [3] A phase II trial of imatinib mesylate (Gleevec®) in myeloproliferative disorders other than CML.
    Kuriakose, P
    Shurafa, MS
    BLOOD, 2004, 104 (11) : 274B - 274B
  • [4] Imitinab (Gleevec) in the treatment of chronic myeloid luekemia (CML)
    Boulos, BM
    Jajeh, A
    Ciobanu, B
    Nawaz, U
    Smiley, T
    Yim, B
    FASEB JOURNAL, 2006, 20 (05): : A1132 - A1132
  • [5] Dose matters: Improved disease control with increased cytoreduction in nonablative BMT for late chronic or accelerated phase CML.
    Champlin, RE
    Khouri, I
    Saliba, R
    Cohen, A
    de Lima, M
    Giralt, S
    BLOOD, 2001, 98 (11) : 478A - 478A
  • [6] Successful bone marrow engrafment after third BMT in accelerated phase CML.
    Manna, A
    Rizzo, C
    Cervellera, M
    Maggi, A
    Barcaglione, P
    Amurri, B
    Palazzo, G
    Mazza, P
    Bacigalupo, A
    BONE MARROW TRANSPLANTATION, 1998, 21 : S81 - S81
  • [7] Preliminary evaluation of the combination of imatinib mesylate (Gleevec) with low dose Ara-C as initial therapy for newly diagnosed chronic phase CML.
    Mauro, MJ
    O'Dwyer, ME
    Stone, RM
    Walker, T
    Wiese, A
    Druker, BJ
    BLOOD, 2002, 100 (11) : 165A - 165A
  • [8] Re-evaluation of daily doses of imatinib for Japanese population in the treatment of chronic phase CML.
    Yamazaki, E
    Shirasugi, Y
    Fukagawa, S
    Sakai, R
    Fujimaki, K
    Harano, H
    Ogawa, Y
    Kanamori, H
    Kishi, K
    Hotta, T
    BLOOD, 2003, 102 (11) : 323B - 324B
  • [9] Life-threatening immune pancytopenia after mud BMT for CML.
    Onida, F
    Pozzoli, E
    Tagliaferri, E
    Annaloro, C
    Della Volpe, A
    Deliliers, GL
    BONE MARROW TRANSPLANTATION, 1998, 21 : S33 - S33
  • [10] Autologous transplantation of in-vivo purged PBSC in chronic phase CML.
    Fischer, T
    Mohm, J
    Duyster, J
    Busemann, C
    Huhn, D
    Bunjes, D
    Neubauer, A
    Ehninger, G
    Kolbe, K
    Hehlmann, R
    Huber, C
    BLOOD, 1999, 94 (10) : 143A - 143A
12345